The worldwide peptide-based weight loss medication market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2025 to 2034. This growth is driven by emerging trends and strong demand across key sectors.
Growth in Patient Volume: The number of patients with obesity is increasing. Additionally, there is a rise in the comorbidities associated with it. Thus, this is increasing the use of peptide-based weight loss medications.
Growing Innovations: There is a rise in the development of different types of peptide-based weight loss medications. Companies are also focusing on developing their various dosage forms for different routes of administration, such as injectables and oral formulations. This is leading to new collaborations among the companies to enhance their development and access.
For instance,
To control appetite and energy metabolism by increasing or mimicking the action of naturally occurring gut hormones, and developing more potent and convenient, single, dual, or triple receptor agonists with improved efficacy is the focus for the R&D of peptide-based weight loss medication.
Key Players: Amgen, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Roche, Pfizer
The clinical trial of the peptide-based weight loss medication focuses on presenting the significant and sustained weight loss with safety, while the regulatory approvals focus on evidence from trials of the benefits of the medications with long-term cardiovascular safety.
Key Players: Novo Nordisk, Amgen, Eli Lilly, Rhythm Pharmaceuticals, Viking Therapeutics
To develop stable and sterile solutions for injectables or oral tablets with improved peptide protection from degradation and enhanced absorption in the bloodstream is the main criterion for formulation and final dosage preparation of peptide-based weight loss medication.
Key Players: Amgen, Novo Nordisk, Viking Therapeutics, Eli Lilly, Roche, Pfizer
In the patient support and service of peptide-based weight loss medication, the financial assistance, savings programs, educational resources, and guidance on nutrition and exercise are provided to the patients to enhance their treatment and manage its side effects.
Key Players: Novo Nordisk, Eli Lilly, WeightWatchers Clinic
In December 2024, after announcing the plans to launch Tirzepatide in the Indian market, the associate vice president and managing director of Eli Lilly (India), Vineet Gupta, stated that, due to growing disease burden of obesity, cancer, and diabetes, a growing population, and increasing health expenditure, a promising market is presented by India. Thus, the combination of these is providing an opportunity to the company. Hence, they will be launching their next line of innovations in India, which will be initiated by the launch of Tirzepatide and the obesity pipeline in 2025.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
